Should I Buy CRDL? CRDL 2026 Analysis

Should You Buy Cardiol Therapeutics Inc (CRDL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.990

1 Day change

3.65%

52 Week Range

1.590

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: trend structure is still bearish (SMA_200 > SMA_20 > SMA_5) and there are no strong catalysts or proprietary buy signals.
If you must act today, the higher-probability play is to avoid new entries until price proves strength by clearing ~1.04–1.07 resistance; otherwise risk of chop/downside remains.
Near-term pattern stats are mixed: next day bias slightly negative (-0.67%) while the 1-week/1-month projections are mildly positive, which doesn’t justify an aggressive immediate buy.

Technical Analysis

Trend: Bearish overall due to moving average stack (SMA_200 > SMA_20 > SMA_5), suggesting the broader trend remains down despite recent stabilization.
Momentum: MACD histogram is positive (0.00109) and expanding, implying improving short-term momentum/attempted reversal.
RSI(6)=61.01: Neutral-to-slightly bullish; not overbought, but also not a deep-value oversold entry.
Key levels: Pivot 0.993; Support S1 0.947 (then 0.919). Resistance R1 1.039 then R2 1.067. A clean break/hold above ~1.04–1.07 would be a clearer technical “go” signal.
Pattern-based expectation: 90% chance of -0.67% next day, +4.26% next week, +1.13% next month (suggests any upside may be slower/less immediate).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Call open interest 19,550 vs put open interest 33 (extreme call-heavy structure); open interest put/call ratio = 0.
Activity today: Call volume 167 vs put volume 0; option volume put/call ratio = 0 (sentiment skewed bullish/speculative, or puts are simply illiquid).
Volatility: 30D IV 119.43 vs historical vol 63.36 (options pricing in very large moves). IV percentile 22 / IV rank 10.41 suggests IV is not elevated versus its own recent history, but absolute IV is still high.
Volume vs average: Today’s volume vs 30D avg = 35.08 (below typical), so the bullish skew is more about existing OI than a surge of fresh flow.
Interpretation: Options market is positioned far more for upside than downside, but thin put activity and low volume reduce confidence as a real-time sentiment confirmation.

Technical Summary

Sell

Buy

Positive Catalysts

- Technical: MACD improving; a breakout above ~1.04–1.07 could trigger momentum follow-through.
- Options structure: Very call-heavy open interest may reflect upside expectations (or structured positioning) if liquidity improves.
- Broader market not strongly risk-off today (S&P 500 -0.07%), so no major index headwind.

Neutral/Negative Catalysts

- No news in the last week: no visible near-term catalyst to force an upside re-rating.
- Trend remains bearish by moving averages; rallies may be sold until the structure flips.
- Extremely high absolute implied volatility (119%+) implies the market expects big swings—price can move sharply against new entries.
- Ownership/trading signals: Hedge funds neutral (no significant trend last quarter) and insiders neutral (no significant trend last month) — limited conviction signals from key cohorts.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: 0 (0.00% YoY) — still pre/early-commercial stage with no demonstrated top-line growth.
Profitability: Net income -9,964,281, down -21.72% YoY (loss widened).
EPS: -0.12, down -33.33% YoY (worsening per-share loss).
Takeaway: Financials indicate continued cash burn/loss-making operations, so the stock is more catalyst/clinical-progress driven than fundamentals-driven right now.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no observable recent Wall Street trend to confirm a bullish (or bearish) stance.
Wall Street-style pros (based on provided data): improving short-term momentum (MACD) and call-heavy options positioning.
Wall Street-style cons (based on provided data): bearish long-term trend structure (moving averages), ongoing losses with no revenue, and lack of near-term news catalysts.
Politicians/Congress: No recent congress trading data available; no politician/influential figure buy/sell signal provided.

2 Analyst Rating

Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.5 USD with a low forecast of 8 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.960

Low

Averages

8.5

High

Current: 0.960

Low

Averages

8.5

High

H.C. Wainwright

Buy

initiated

AI Analysis

2025-06-02

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-06-02

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-16

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

CRDL Should I Buy

CRDL Should I Buy

Should You Buy Cardiol Therapeutics Inc (CRDL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch